Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

SRPT

Sarepta Therapeutics Inc

May 17 • 04:00PM ET

131.38

Dollar change -1.36
Percentage change -1.02	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VXF VBK IBB IWP IWF IWR SCHM VHT

Index	-	P/E	1975.64	EPS (ttm)	0.07	Insider Own	6.10%	Shs Outstand	93.73M	Perf Week	-0.33%
Market Cap	12.42B	Forward P/E	13.12	EPS next Y	10.01	Insider Trans	-0.48%	Shs Float	88.76M	Perf Month	12.72%
Income	16.90M	PEG	-	EPS next Q	-0.10	Inst Own	87.10%	Short Float	6.41%	Perf Quarter	-2.40%
Sales	1.40B	P/S	8.85	EPS this Y	156.79%	Inst Trans	6.35%	Short Ratio	6.33	Perf Half Y	56.85%
Book/sh	10.17	P/B	12.92	EPS next Y	204.06%	ROA	0.54%	Short Interest	5.69M	Perf Year	-11.69%
Cash/sh	14.71	P/C	8.93	EPS next 5Y	-	ROE	2.02%	52W Range	55.25 - 152.21	Perf YTD	36.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.21%	ROI	0.76%	52W High	-13.69%	Beta	0.96
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	32.89%	Gross Margin	85.20%	52W Low	137.79%	ATR (14)	4.64
Dividend Ex-Date	-	Current Ratio	4.05	EPS Y/Y TTM	101.12%	Oper. Margin	-6.76%	RSI (14)	56.17	Volatility	2.60% 4.13%
Employees	1314	Debt/Eq	1.44	Sales Y/Y TTM	43.83%	Profit Margin	1.20%	Recom	1.38	Target Price	170.00
Option/Short	Yes / Yes	LT Debt/Eq	1.33	EPS Q/Q	106.22%	Payout	-	Rel Volume	0.94	Prev Close	132.74
Sales Surprise	8.94%	EPS Surprise	2768.22%	Sales Q/Q	63.10%	Earnings	May 01 AMC	Avg Volume	898.92K	Price	131.38
SMA20	1.92%	SMA50	4.12%	SMA200	15.83%	Trades		Volume	848,974	Change	-1.02%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$170
Dec-13-23	Resumed	Citigroup	Buy	$113
Dec-12-23	Initiated	Deutsche Bank	Buy	$109
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$166 → $40
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line	$139
Apr-26-23	Initiated	SMBC Nikko	Outperform	$185
Apr-04-23	Initiated	Citigroup	Buy	$179
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$141 → $187
Dec-22-22	Reiterated	BTIG Research	Buy	$125 → $160
Dec-16-22	Upgrade	UBS	Neutral → Buy	$100 → $158
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$140
Jan-05-22	Reiterated	Needham	Buy	$157 → $150
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform	$125
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight	$130
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral	$92 → $87
Jun-15-21	Initiated	BTIG Research	Buy	$110

Show Previous Ratings

May-17-24 08:05AM	Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating (MT Newswires)
May-14-24 07:30AM	Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180 (MT Newswires)
May-04-24 12:00PM	3 Biotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace)
May-03-24 10:07AM	Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health (Business Wire)
May-02-24 03:42PM	Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says (MT Newswires)
11:30AM	Loading…
11:30AM	UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating (MT Newswires)
11:13AM	Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
11:08AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:52AM	Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating (MT Newswires)
06:01AM	Q1 2024 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:32AM	Sarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-01-24 08:55PM	SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:30PM	Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:30PM	Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript (Motley Fool)
05:20PM	Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates (Zacks)
05:06PM	Loading…
05:06PM	Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours (MT Newswires)
04:19PM	Sarepta Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments (Business Wire)
09:15AM	1 Top Growth Stock to Buy and Hold for 10 Years (Motley Fool)
Apr-30-24 06:38PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:28AM	Why Sarepta (SRPT) Might Surprise This Earnings Season (Zacks)
Apr-29-24 03:20PM	Sarepta Therapeutics Stock Shows Improved Technical Strength (Investor's Business Daily)
Apr-24-24 08:30AM	Sarepta Therapeutics to Announce First Quarter 2024 Financial Results (Business Wire) +6.09%
Apr-13-24 09:39PM	10 Unstoppable Stocks That Will Make You Richer (Insider Monkey)
Apr-08-24 04:13PM	Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst (Investor's Business Daily)
Apr-06-24 08:45AM	2 Biotech Stocks to Buy Hand Over Fist in April (Motley Fool)
Apr-02-24 07:04AM	Outperforming ETF manager names a potential 50-bagger in the stock market (MarketWatch)
Mar-29-24 04:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:30AM	Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-26-24 07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
10:00AM	Loading…
Mar-25-24 10:00AM	A Comprehensive Look at Sarepta's Growth and Innovation (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 03:53PM	Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-13-24 08:00AM	Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? (Motley Fool)
Mar-12-24 01:18AM	Director Wigzell Hans Lennart Rudolf Sells 15,000 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Mar-11-24 09:03AM	Billionaire Ray Dalio and Insiders Love These 10 Stocks (Insider Monkey)
Mar-06-24 11:54PM	Director Stephen Mayo Sells 3,135 Shares of Sarepta Therapeutics Inc (SRPT) (GuruFocus.com)
Mar-04-24 09:47AM	Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst (Motley Fool)
08:30AM	Sarepta Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Mar-02-24 12:05AM	Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight (GuruFocus.com)
Feb-29-24 06:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.98%
12:35PM	Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
10:52AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
12:00AM	Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript (Motley Fool)
Feb-28-24 06:00PM	Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:23PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments (Business Wire)
07:15AM	Is It Too Late to Buy Sarepta Therapeutics Stock? (Motley Fool)
Feb-27-24 08:48AM	Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) (Zacks)
Feb-21-24 11:24AM	Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates? (Zacks)
08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-20-24 10:00AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-19-24 03:26AM	Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last? (Zacks)
Feb-16-24 11:23AM	Why Sarepta Therapeutics Stock Is Soaring Today (Motley Fool) +7.78%
11:22AM	Prospects Look Better for Sarepta Gene Therapy, Sending the Stock Up Again (Barrons.com)
08:46AM	UPDATE 3-US FDA to review Sarepta's Duchenne gene therapy for traditional approval (Reuters)
07:41AM	CORRECTED-UPDATE 1-US FDA to review Sarepta's Duchenne gene therapy for traditional approval (Reuters)
07:22AM	U.S. FDA to not conduct advisers' meet for Sarepta's Duchenne gene therapy (Reuters)
07:00AM	Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication (Business Wire)
Feb-15-24 07:45AM	2 Magnificent Growth Stocks to Buy With $500 (Motley Fool)
Feb-11-24 01:45AM	1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? (Motley Fool)
Jan-31-24 06:29PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-29-24 07:37AM	UPDATE 3-Sarepta's new Duchenne drug outperforms bestseller Exondys in trial (Reuters)
07:12AM	REFILE-Sarepta says its experimental Duchenne drug more effective than older medicine (Reuters)
07:00AM	Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 (Business Wire)
06:50AM	Sarepta data show new Duchenne drugs potency, but highlight side effects (BioPharma Dive)
Jan-26-24 05:15AM	Got $3,000? 3 Growth Stocks to Double Up On Right Now (Motley Fool)
Jan-25-24 09:45AM	Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals? (Motley Fool)
Jan-22-24 05:47PM	Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today (Motley Fool)
09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 29.51%: Read This Before Placing a Bet (Zacks)
09:38AM	Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates (Insider Monkey)
Jan-16-24 03:57PM	Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market (InvestorPlace)
09:02AM	Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 (Business Wire)
Jan-10-24 11:43AM	Sarepta Rebounded. Its Gene Therapy Is Back on Course. (Barrons.com)
06:17AM	Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains? (Zacks)
Jan-09-24 11:22AM	Why Is Sarepta Therapeutics (SRPT) Stock Up Today? (InvestorPlace) +16.72%
10:52AM	Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results (Zacks)
07:15AM	2 Growth Stocks That Could Make You Richer in 2024 and Beyond (Motley Fool)
Jan-08-24 11:55AM	Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue (Business Wire) +5.41%
Jan-04-24 09:55AM	Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade (Zacks)
Jan-02-24 08:30AM	Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-29-23 06:27PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:44AM	Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Dec-28-23 10:07AM	3 Things About Sarepta Therapeutics Every Smart Investor Knows (Motley Fool)
Dec-27-23 06:26PM	15 Best Fast Growth Stocks to Buy Now (Insider Monkey)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
Dec-22-23 02:49PM	Sarepta Therapeutics Seen Expanding Duchenne Treatment Label (Barrons.com)
10:15AM	Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? (Motley Fool)
08:00AM	Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status (Business Wire)
06:33AM	Sarepta tests FDA flexibility with bid to expand Duchenne gene therapys approval (BioPharma Dive)
Dec-17-23 09:45AM	1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond (Motley Fool)
Dec-15-23 09:55AM	Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? (Zacks)
Dec-12-23 12:43PM	10 Beaten Down Stocks Billionaires Are Crazy About (Insider Monkey)
Dec-09-23 07:00AM	Could Sarepta Therapeutics Stock Help You Become a Millionaire? (Motley Fool)
Dec-01-23 11:31AM	Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-30-23 06:34PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet (Zacks)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:26AM	13 Stocks Insiders are Buying Now (Insider Monkey)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murray Dallan	Chief Customer Officer	May 02 '24	Sale	140.00	3,635	508,900	18,125	May 06 08:09 PM
Boor Kathryn Jean	Director	Mar 11 '24	Sale	122.93	761	93,550	7,516	Mar 11 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Option Exercise	13.90	15,000	208,500	37,840	Mar 11 08:02 PM
Wigzell Hans Lennart Rudolf	Director	Mar 08 '24	Sale	123.25	15,000	1,848,795	22,840	Mar 11 08:02 PM
Mayo Stephen	Director	Mar 05 '24	Sale	122.96	3,135	385,480	6,621	Mar 06 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Mar 01 '24	Sale	128.84	2,000	257,676	26,836	Mar 05 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Mar 01 '24	Sale	125.34	2,000	250,680	31,827	Mar 05 08:00 PM
Estepan Ian Michael	Chief Financial Officer	Mar 01 '24	Sale	128.30	1,200	153,960	39,114	Mar 05 08:00 PM
BEHRENS M KATHLEEN	Director	Nov 03 '23	Option Exercise	29.03	15,000	435,450	174,993	Nov 06 08:00 AM
Barry Richard	Director	Nov 03 '23	Buy	78.81	50,000	3,940,500	140,000	Nov 06 08:00 AM
INGRAM DOUGLAS S	President & CEO	Nov 03 '23	Buy	79.36	25,225	2,001,800	390,307	Nov 06 08:00 AM
Chambers Michael Andrew	Director	Aug 14 '23	Buy	109.47	9,979	1,092,429	246,996	Aug 15 08:00 AM
Chambers Michael Andrew	Director	Aug 11 '23	Buy	108.05	23,686	2,559,272	237,017	Aug 14 08:00 AM
Chambers Michael Andrew	Director	Aug 10 '23	Buy	106.15	34,867	3,701,067	213,331	Aug 11 07:40 AM
Wigzell Hans Lennart Rudolf	Director	Aug 04 '23	Option Exercise	29.03	15,000	435,450	35,994	Aug 08 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 04 '23	Sale	106.72	15,000	1,600,800	20,994	Aug 08 08:00 PM

Open in Screener

SAVA

Cassava Sciences Inc

May 17 • 04:00PM ET

23.12

Dollar change +1.56
Percentage change 7.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA VTWO VHT IHE ITOT VTWG

Index	RUT	P/E	-	EPS (ttm)	-2.16	Insider Own	7.11%	Shs Outstand	47.98M	Perf Week	14.29%
Market Cap	1.11B	Forward P/E	64.22	EPS next Y	0.36	Insider Trans	0.00%	Shs Float	44.57M	Perf Month	9.11%
Income	-47.90M	PEG	-	EPS next Q	-0.41	Inst Own	24.81%	Short Float	31.11%	Perf Quarter	-2.65%
Sales	0.00M	P/S	-	EPS this Y	53.74%	Inst Trans	5.13%	Short Ratio	16.43	Perf Half Y	5.96%
Book/sh	1.82	P/B	12.72	EPS next Y	133.54%	ROA	-25.63%	Short Interest	13.87M	Perf Year	-8.58%
Cash/sh	2.59	P/C	8.93	EPS next 5Y	-	ROE	-33.90%	52W Range	12.32 - 32.10	Perf YTD	2.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-30.45%	ROI	-60.95%	52W High	-27.98%	Beta	-0.50
Dividend TTM	-	Quick Ratio	1.74	Sales past 5Y	0.00%	Gross Margin	-	52W Low	87.66%	ATR (14)	1.40
Dividend Ex-Date	Dec 13, 2012	Current Ratio	1.74	EPS Y/Y TTM	43.36%	Oper. Margin	0.00%	RSI (14)	56.30	Volatility	7.69% 5.47%
Employees	29	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	104.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	26.90%	Payout	-	Rel Volume	0.92	Prev Close	21.56
Sales Surprise	-	EPS Surprise	6.52%	Sales Q/Q	-	Earnings	May 10 AMC	Avg Volume	843.78K	Price	23.12
SMA20	7.29%	SMA50	8.50%	SMA200	8.33%	Trades		Volume	772,891	Change	7.24%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral	$44
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$100
Jul-07-21	Reiterated	Maxim Group	Buy	$80 → $190
Apr-27-21	Initiated	B. Riley Securities	Buy	$78
Feb-16-21	Reiterated	H.C. Wainwright	Buy	$20 → $66
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$24
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy	$20
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy	$3 → $12

May-10-24 08:53PM	SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam (GlobeNewswire)
May-08-24 11:00AM	Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution (GlobeNewswire)
May-01-24 09:10AM	Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ (GlobeNewswire)
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
09:20AM	Loading…
Apr-15-24 09:20AM	Redemption Date Announced for Warrants (GlobeNewswire) -12.04%
Mar-25-24 09:13AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire)
Mar-13-24 10:45AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava (PR Newswire)
Mar-04-24 09:15AM	Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference (GlobeNewswire)
Feb-28-24 09:14AM	Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-23-24 11:30AM	CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Feb-08-24 10:39AM	Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial (InvestorPlace)
Feb-07-24 09:08AM	No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months (GlobeNewswire) +7.35%
Feb-05-24 02:35PM	Cassava Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-05-24 11:46AM	New SAVAW Warrants Are Trading After Cassava Sciences' Distribution (InvestorPlace)
09:12AM	Loading…
09:12AM	Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool)
Dec-15-23 06:06PM	Why Cassava Sciences Stock Zoomed 21% Higher This Week (Motley Fool)
Dec-13-23 11:10AM	Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days (Investor's Business Daily)
Dec-12-23 02:02PM	Why Is Cassava Sciences (SAVA) Stock Up 15% Today? (InvestorPlace) +5.96%
09:13AM	Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-08-23 07:31PM	Why Cassava Sciences Stock Soared Today (Motley Fool) +17.37%
Dec-07-23 04:01PM	Cassava Sciences Appoints Three New Members to its Board of Directors (GlobeNewswire)
Nov-14-23 09:53PM	7 High-Risk, High-Reward Stocks for the Extreme Contrarian (InvestorPlace) +13.90%
Nov-07-23 09:39AM	Cassava Sciences Inc (SAVA) Reports Q3 2023 Financial Results (GuruFocus.com)
09:01AM	Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Nov-06-23 09:15AM	Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease (GlobeNewswire) -5.81%
Oct-31-23 08:15AM	1 Big Red Flag to Fear When a Stock Is Down (Motley Fool) +6.39%
Oct-25-23 09:15AM	MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA) (GlobeNewswire) +25.80%
Oct-19-23 09:59AM	7 Stocks That Are Heading for a Train Wreck (InvestorPlace) +5.32%
07:01PM	Loading…
Oct-16-23 07:01PM	Is This The End Of Naked Short Selling? (Oilprice.com) -14.94%
05:26PM	SAVA Stock Continues to Plunge on Misconduct Allegations (InvestorPlace)
Oct-13-23 03:29PM	Cassava Sciences Adviser Found to Have Committed Egregious Misconduct (The Wall Street Journal) -15.28%
03:29PM	Alzheimers Researcher Found to Have Committed Misconduct (The Wall Street Journal)
12:45PM	Why Cassava Sciences Stock Is Tanking Today (Motley Fool)
11:21AM	SAVA Stock Alert: Cassava Sciences Addresses Leaked Report (InvestorPlace)
Oct-12-23 11:43PM	Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press (GlobeNewswire)
Oct-06-23 03:13PM	Why Shares of Cassava Sciences Soared This Week (Motley Fool)
Oct-05-23 09:15AM	Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY (GlobeNewswire)
Oct-02-23 09:00AM	Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer's Disease (GlobeNewswire)
Sep-18-23 09:15AM	Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimers Disease (GlobeNewswire) -5.31%
Sep-14-23 06:30AM	The 7 Best Meme Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-13-23 05:20PM	Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimers Disease (GlobeNewswire)
Sep-11-23 09:10AM	Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimers Disease (GlobeNewswire)
Sep-06-23 09:15AM	Cassava Sciences Invited to Present in Four Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey) +8.87%
Aug-03-23 09:07AM	Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates (GlobeNewswire)
Jul-29-23 11:30AM	Top 12 Small-Cap Stocks With Highest Upside Potential (Insider Monkey)
Jul-13-23 07:31AM	Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now (InvestorPlace)
Jul-05-23 11:44AM	Why Shares of Cassava Sciences Are Dropping Wednesday (Motley Fool) -12.95%
09:15AM	Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimers Disease (GlobeNewswire)
Jun-27-23 09:15AM	New Research Shows Simufilam Suppresses Overactive mTOR (GlobeNewswire)
Jun-12-23 10:19AM	Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth (Simply Wall St.)
09:15AM	New Publication Highlights Basic Science Supporting Simufilam (GlobeNewswire)
Jun-01-23 09:15AM	Cassava Sciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-30-23 12:06PM	Cassava (SAVA) Up on Progress With Alzheimers Disease Study (Zacks)
May-23-23 09:50AM	3 Biotech Stocks to Avoid Like the Plague (InvestorPlace)
May-12-23 04:39PM	Why Shares of Cassava Sciences Jumped This Week (Motley Fool) -5.06%
May-11-23 02:40PM	Cassava Sciences Stock Clears Benchmark, Hitting 80-Plus RS Rating (Investor's Business Daily)
09:15AM	Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimers Disease (GlobeNewswire)
May-08-23 09:15AM	New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A (GlobeNewswire)
May-01-23 09:00AM	Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates (GlobeNewswire)
Apr-26-23 09:12AM	Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference (GlobeNewswire)
Mar-09-23 09:45AM	3 Short-Squeeze Stocks to Keep on Your Radar (InvestorPlace)
Mar-04-23 07:20AM	The three-year returns have been massive for Cassava Sciences (NASDAQ:SAVA) shareholders despite underlying losses increasing (Simply Wall St.)
Mar-03-23 07:07AM	Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-23 09:15AM	Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates (GlobeNewswire)
Feb-24-23 01:29PM	3 Drug Stocks to Watch as Alzheimers Clinical Trials End (InvestorPlace)
Feb-08-23 09:15AM	Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimers Disease (GlobeNewswire)
Feb-01-23 08:55AM	3 Big Reasons to Sell Cassava Sciences Stock Right Now (Motley Fool)
Jan-25-23 08:27PM	Why the Dip in Cassava Sciences (SAVA) Stock Shouldnt Spook You (TipRanks) -6.62%
Jan-24-23 04:06PM	Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors (Investor's Business Daily) -19.21%
12:22PM	Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results (Benzinga)
09:15AM	Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimers Disease (GlobeNewswire)
Jan-18-23 10:35AM	Cassava Sciences Stock Shows Big Jump In Its Relative Strength Rating (Investor's Business Daily)
Jan-12-23 09:40AM	Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-03-23 09:16AM	Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst individual investors who own 69% of the shares, institutions hold 25% (Simply Wall St.) -6.03%
Dec-20-22 09:15AM	Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD (GlobeNewswire)
Dec-06-22 09:15AM	Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimers Disease (GlobeNewswire)
Nov-22-22 12:30PM	Cassava Sciences Announces Closing of $50 Million Registered Direct Offering (GlobeNewswire)
Nov-18-22 01:30PM	Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock (GlobeNewswire)
Nov-16-22 10:43AM	7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022 (InvestorPlace) -13.04%
Nov-15-22 10:00AM	Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study (Benzinga)
Nov-14-22 03:54PM	Cassava Sciences stock pops after rival experiences setback in Alzheimers research (Yahoo Finance Video) +9.44%
Nov-07-22 09:00AM	Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates (GlobeNewswire)
06:15AM	What the Latest Controversy Really Means for SAVA Stock (InvestorPlace)
Nov-04-22 10:49AM	Short sellers hit back at Cassava lawsuit against them: We stand behind everything we wrote (MarketWatch)
Nov-03-22 09:15AM	Cassava Sciences Files Lawsuit Against Perpetrators of Short and Distort Campaign (GlobeNewswire)
Nov-01-22 02:21PM	Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store? (Zacks)
Oct-31-22 05:50PM	Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know (Zacks)
06:15AM	A New Study Makes Cassava Sciences Stock an Interesting Buy (InvestorPlace)
Oct-27-22 09:15AM	Cassava Sciences Announces Expansion of Leadership Team (GlobeNewswire)
Oct-25-22 05:50PM	Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know (Zacks)
Oct-17-22 05:50PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know (Zacks)
Oct-13-22 09:15AM	Cassava Sciences Announces Initiation of an Open-label Extension Study (GlobeNewswire)
Oct-11-22 06:00PM	Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know (Zacks)
06:00AM	Dont Let Misconduct Allegations Cloud Your Perception of SAVA Stock (InvestorPlace)
Oct-05-22 06:15AM	2 Signals to Watch Before Buying SAVA Stock (InvestorPlace)
Sep-30-22 10:35AM	How High Can SAVA Stock Go Once the Controversy Clears? (InvestorPlace)
Sep-29-22 06:15PM	Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know (Zacks)

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERTSON SANFORD	Director	Apr 26 '24	Option Exercise	22.00	69,000	1,518,000	955,851	Apr 30 09:13 AM
Barry Richard	Director	Apr 23 '24	Option Exercise	22.00	176,085	3,873,870	469,562	Apr 25 09:15 AM
Kupiec James William	Chief Medical Officer	Apr 18 '24	Option Exercise	22.00	1,500	33,000	4,000	Apr 22 09:19 AM
Schoen Eric	Chief Financial Officer	Apr 17 '24	Option Exercise	22.00	1,500	33,000	21,300	Apr 17 04:21 PM
ROBERTSON SANFORD	Director	Aug 23 '23	Buy	17.45	30,000	523,500	886,851	Aug 24 04:06 PM
Barry Richard	Director	Aug 22 '23	Buy	16.65	16,571	275,907	293,477	Aug 23 04:58 PM
Barry Richard	Director	Aug 21 '23	Buy	16.80	1,906	32,021	276,906	Aug 23 04:58 PM
SCANNON PATRICK J MD PHD	Director	Jun 12 '23	Option Exercise	0.95	1,000	950	1,000	Jun 12 04:53 PM
BARBIER REMI	President and CEO	May 24 '23	Option Exercise	16.87	71,428	1,204,990	782,002	May 25 05:11 PM
BARBIER REMI	President and CEO	May 24 '23	Option Exercise	16.87	14,285	240,988	390,397	May 25 05:11 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SRPT

Sarepta Therapeutics Inc

SAVA

Cassava Sciences Inc

Upgrade your FINVIZ experience